Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 5/20 | 0.33 |
| ▸ | HTR7 | P34969 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16974355 | 0.90 | TP53 (0.40) | TP53THRBHTR1AHTR7DRD2 | |
| SCHEMBL30943672 | 0.85 | KDM4E (0.37) | TP53THRBMEN1KMT2ALMNA | |
| SCHEMBL29742315 | 0.83 | TP53 (0.43) | TP53THRBMEN1KMT2ALMNA | |
| SCHEMBL15326722 | 0.82 | TP53 (0.42) | TP53MEN1KMT2ALMNAGAA | |
| SCHEMBL29603305 | 0.80 | TP53 (0.37) | TP53HTR1AHTR7DRD2HTR6 | |
| SCHEMBL31199169 | 0.80 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL31041095 | 0.80 | HTT (0.49) | THRBMEN1KMT2AALDH1A1 | |
| SCHEMBL31041209 | 0.80 | HTT (0.49) | THRBMEN1KMT2AALDH1A1 | |
| SCHEMBL31041190 | 0.80 | HTT (0.49) | THRBMEN1KMT2AALDH1A1 | |
| SCHEMBL23519429 | 0.79 | TP53 (0.37) | TP53HTR1AHTR7DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135012-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| EP-4404972-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | The Johns Hopkins University (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023049743-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135012-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | FCGR2A, FCGR3B, SLC11A2 | TP53 221/4885THRB 1886/4885HTR1A 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.